Class information for:
Level 2: CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//AZECINES

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3413 1150 26.5 66%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 3)


ID, lev.
above		 Publications Label for level above
189 51017 CLOPIDOGREL//PLATELETS//PRASUGREL

Classes in level below (level 1)


ID, lev. below Publications Label for level below
16885 566 CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//CAS 73963 72 1
24880 249 REFORMATSKY REACTION//ASYMMETRIC REFORMATSKY REACTION//CHIRAL AMINOALCOHOLS
25780 224 AZECINES//LEHRSTUHL PHARMAZEUT MED CHEM//LE300
32204 111 MOUSE LYMPHOID NEOPLASMA P 388//MOUSE MAMMARY CARCINOMA FM 3A//HUMAN HISTIOCYTIC LYMPHOMA U 937

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CILOSTAZOL Author keyword 242 57% 25% 290
2 CLIN PHARMACOKINET PHARMACODYNAM METAB Address 15 82% 1% 9
3 AZECINES Author keyword 11 100% 1% 6
4 REFORMATSKY REACTION Author keyword 8 24% 3% 30
5 LEHRSTUHL PHARMAZEUT MED CHEM Address 8 37% 1% 17
6 CAS 73963 72 1 Author keyword 6 80% 0% 4
7 TRIPLE ANTIPLATELET THERAPY Author keyword 6 58% 1% 7
8 LE300 Author keyword 6 100% 0% 4
9 AZECINE Author keyword 4 67% 0% 4
10 ASYMMETRIC REFORMATSKY REACTION Author keyword 4 75% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CILOSTAZOL 242 57% 25% 290 Search CILOSTAZOL Search CILOSTAZOL
2 AZECINES 11 100% 1% 6 Search AZECINES Search AZECINES
3 REFORMATSKY REACTION 8 24% 3% 30 Search REFORMATSKY+REACTION Search REFORMATSKY+REACTION
4 CAS 73963 72 1 6 80% 0% 4 Search CAS+73963+72+1 Search CAS+73963+72+1
5 TRIPLE ANTIPLATELET THERAPY 6 58% 1% 7 Search TRIPLE+ANTIPLATELET+THERAPY Search TRIPLE+ANTIPLATELET+THERAPY
6 LE300 6 100% 0% 4 Search LE300 Search LE300
7 AZECINE 4 67% 0% 4 Search AZECINE Search AZECINE
8 ASYMMETRIC REFORMATSKY REACTION 4 75% 0% 3 Search ASYMMETRIC+REFORMATSKY+REACTION Search ASYMMETRIC+REFORMATSKY+REACTION
9 MOUSE LYMPHOID NEOPLASMA P 388 4 75% 0% 3 Search MOUSE+LYMPHOID+NEOPLASMA+P+388 Search MOUSE+LYMPHOID+NEOPLASMA+P+388
10 MOUSE MAMMARY CARCINOMA FM 3A 4 75% 0% 3 Search MOUSE+MAMMARY+CARCINOMA+FM+3A Search MOUSE+MAMMARY+CARCINOMA+FM+3A

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHROMOSOME 10 PHOSPHORYLATION 31 92% 1% 12
2 EXPERIMENTAL THROMBOSIS 20 59% 2% 22
3 PHOSPHODIESTERASE INHIBITOR 15 27% 4% 49
4 TREATING INTERMITTENT CLAUDICATION 12 75% 1% 9
5 METHYLIDENE GAMMA BUTYROLACTONES 11 69% 1% 9
6 ALKYLPEROXIDE 10 73% 1% 8
7 PHOSPHODIESTERASE TYPE 3 9 67% 1% 8
8 CILOSTAZOL 8 19% 3% 40
9 2 OXOQUINOLINE DERIVATIVES 8 50% 1% 11
10 AMP PHOSPHODIESTERASE INHIBITOR 6 80% 0% 4

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention 2008 64 35 71%
CILOSTAZOL 1993 50 22 82%
Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials 2009 46 43 60%
The pharmacology of cilostazol 2002 70 16 94%
Cilostazol (Pletal (R)): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake 2001 92 70 64%
Cilostazol as a unique antithrombotic agent 2003 100 132 56%
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin 2011 14 26 69%
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons 2014 3 45 44%
Recent Advances in the Catalytic Enantioselective Reformatsky Reaction 2013 3 45 76%
Cilostazol for intermittent claudication 2014 2 31 48%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLIN PHARMACOKINET PHARMACODYNAM METAB 15 82% 0.8% 9
2 LEHRSTUHL PHARMAZEUT MED CHEM 8 37% 1.5% 17
3 MED I EM TISSUE REGENERAT 3 15% 1.4% 16
4 BULK PHARMACEUT CHEM 2 67% 0.2% 2
5 ADV PHARMACOL 2 50% 0.3% 3
6 CLIN PK PD METAB 1 50% 0.2% 2
7 GEFASSZENTRUM OBERRHEIN MANNHEIM SPEYER 1 50% 0.2% 2
8 NEW DRUG DISCOVERY 1 1 16% 0.5% 6
9 EXECUT DEANS OFF 1 40% 0.2% 2
10 MERIDIAN STRUCT MED 1 11% 0.7% 8

Related classes at same level (level 2)


Rank Relatedness score Related classes
1 0.0000016086 PERIPHERAL ARTERIAL DISEASE//INTERMITTENT CLAUDICATION//ANKLE BRACHIAL INDEX
2 0.0000013351 CLOPIDOGREL//PRASUGREL//ASPIRIN RESISTANCE
3 0.0000010783 ROLIPRAM//PHOSPHODIESTERASE//PDE4
4 0.0000007340 2 5 DI TERT BUTYL P BENZOQUINONE//METAL CONTAINING TRIOXIDES//TRI TERT BUTOXYALUMINUM
5 0.0000006968 CARBENE COMPLEXES//1 BETA METHYLCARBAPENEM//AZETIDIN 2 ONES
6 0.0000006705 ORGANOCATALYSIS//ASYMMETRIC CATALYSIS//BAYLIS HILLMAN ADDUCTS
7 0.0000006558 LEVOSIMENDAN//CALCIUM SENSITIZERS//CALCIUM SENSITIZER
8 0.0000006178 POLYNUCLEOTIDE ANALOGUE//QUIM FARMACEUT ORGAN//BENZODIOXEPINS
9 0.0000005601 HETEROCYCL CPDS//CENTHAQUIN//FOSTEDIL
10 0.0000005552 INTIMA MEDIA THICKNESS//CAROTID ARTERIES//VASA VASORUM